Abstracts Archive - Page 2300 of 2425 - ACR Meeting Abstracts

Abstract Number: 1823 • 2012 ACR/ARHP Annual Meeting
Short Periods of Glucocorticoid Use Increase the Risk of Gastrointestinal Bleeding
Steven C. Vlad¹, David T. Felson², Donald R. Miller³ and Yuqing Zhang⁴, ¹Clinical Epidemiology, Boston University, Boston, MA, ²Boston University, Boston, MA, ³Center for Health Quality, Outcomes, and Economic Research, Edith Nourse Rogers Memorial VA Hospital, Bedford, MA, ⁴Clinical Epidemiology Unit, Boston University, Boston, MA
Background/Purpose: Short term use of glucocorticoids (GCs) is thought to be relatively benign and most adverse events have been studied in chronic users; there is…
Abstract Number: 1824 • 2012 ACR/ARHP Annual Meeting
Do Statins Reduce the Incidence of Connective Tissue Disease? A Retrospective Cohort Study
Thomas W. Schmidt¹, Daniel F. Battafarano¹, Christopher R. Frei², Eric M. Mortensen³ and Ishak Mansi⁴, ¹Rheumatology, San Antonio Military Medical Center, San Antonio, TX, ²Pharmacotherapy Education and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Internal Medicine, San Antonio Military Medical Center, San Antonio, TX
Background/Purpose: Due to their anti-inflammatory effects, statins were proposed to lower the incidence of connective tissue diseases (CTD). The objective of this study is to…
Abstract Number: 1825 • 2012 ACR/ARHP Annual Meeting
Work Disability and Work Limitations in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Are Equal and Increase with Comorbidities
Chanseok Rhee¹, Janet E. Pope², Andrew E. Thompson³, Nicole G. H. Le Riche⁴, Gina Rohekar⁵ and Sherry Rohekar⁵, ¹School of Medicine and Dentistry, Schulich School of Medicine and Dentisty, Western University, London, ON, Canada, ²Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ³Rheumatology, St. Josephs Health Ctr, London, ON, Canada, ⁴Department of Medicine, St. Joseph's Hospital, London, ON, Canada, ⁵Rheumatology, St. Joseph's Hospital, London, ON, Canada
Background/Purpose: Few studies directly compare work disability (WD) and work productivity losses in different forms of inflammatory arthritis (IA) such as rheumatoid arthritis (RA), psoriatic…
Abstract Number: 1826 • 2012 ACR/ARHP Annual Meeting
Intravenously Administered Golimumab Significantly Improves Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis: Results of a Phase III, Placebo Controlled Trial
Rene Westhovens¹, Michael Weinblatt², Chenglong Han³, Tim Gathany⁴, Lilianne Kim⁵, Michael Mack⁶, Jiandong Lu⁷, Daniel Baker⁸, Alan Mendelsohn⁸ and Clifton O. Bingham III⁹, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Outcomes Research, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, ⁴Janssen Global Services, LLC., Malvern, PA, ⁵Janssen Research & Development, a division of Pharmaceutical Research & Development LLC, Janssen Research & Development, LLC, Spring House, PA, ⁶Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁷Biostatistics, Janssen Research & Development, LLC, Spring House, PA, ⁸Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁹Department of Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: To evaluate the impact of intravenously (IV) administered golimumab (GLM) on health related quality of life (HRQoL) and work productivity in patients (pts) with…
Abstract Number: 1827 • 2012 ACR/ARHP Annual Meeting
Factors That Impact Work Productivity in the Preserve Trial: A Randomized Controlled Trial of Combination Etanercept-Methotrexate Therapy in Patients with Moderately Active Rheumatoid Arthritis
Vibeke Strand¹, Thomas V. Jones², Wenzhi Li³, Andrew S. Koenig⁴ and Sameer Kotak⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ²Inflammation Specialty Care, Pfizer, Inc, Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, ⁵Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Active joint inflammation and structural damage in patients with rheumatoid arthritis (RA) often result in impaired physical function and ultimately work disability.1,2 Lost productivity…
Abstract Number: 1828 • 2012 ACR/ARHP Annual Meeting
Smoking Is Associated with Worse and More Widespread Pain, Worse Fatigue, General Health and Quality of Life in a Swedish Population Based Cohort of Patients with Psoriatic Arthritis
Ann B. I. Bremander¹, Lennart TH Jacobsson², Stefan Bergman³, Emma Haglund⁴ and Ingemar F. Petersson⁵, ¹Department of Exercise Physiology, Biomechanics and Health, Halmstad University School of Business and Engineering, Halmstad, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ³Spenshult Research and Development Center, Halmstad, Sweden, ⁴Research and Development Centre, Spenshult Hospital for Rheumatic Diseases, Halmstad, Sweden, ⁵Lund University, Lund, Sweden
Background/Purpose: Smoking has been found to be associated with an increased risk of developing psoriatic arthritis (PsA). The purpose of this study was analyse possible…
Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting
Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
Machaon Bonafede¹, Crystal Watson², George Joseph², Nicole Princic¹ and David J. Harrison², ¹Thomson Reuters Healthcare, Cambridge, MA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…
Abstract Number: 1830 • 2012 ACR/ARHP Annual Meeting
Drugs Are the Major Cost Driver of Rheumatoid Arthritis As Soon As the First Year of the Disease: An Economic Analysis Based On the Espoir Cohort Data
Bruno Fautrel¹, Sandy Lucier², Georges Haour², Hassani Maoulida², Stephanie Harvard¹, Alain Saraux³, Xavier Mariette⁴, Francis Guillemin⁵, Isabelle Durand-Zaleski² and Karine Chevreul², ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²APHP - URC Eco, Paris, France, ³Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁵Hopitaux de Brabois, Nancy, France
Background/Purpose: Many studies have explored the economic burden of established RA but few data are available about the determinants of costs in early rheumatoid arthritis…
Abstract Number: 1831 • 2012 ACR/ARHP Annual Meeting
Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database
Eiichi Tanaka¹, Eisuke Inoue², Daisuke Hoshi³, Akiko Kobayashi², Naoki Sugimoto², Kumi Shidara², Eri Sato³, Yasushi Inoue³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara³, Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA), a chronic inflammatory disorder, causes a significant decrease in quality of life. Recently developed biologic agents (BAs) have caused a considerable…
Abstract Number: 1832 • 2012 ACR/ARHP Annual Meeting
Evaluating the Cost-Effectiveness of Personalized Treatment with Adalimumab Using Serum Drug Levels in Rheumatoid Arthritis Patients
Charlotte L. M. Krieckaert¹, Sandhya C. Nair², M. T. Nurmohamed³, Carlo J.J. van Dongen¹, Willem F. Lems⁴, Floris P.J.G. Lafeber², J.W.J. Bijlsma⁵, Gertjan Wolbink¹ and Paco M.J. Welsing⁶, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Rheumatology & Clinical Immunology, F02.127, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The high costs of biologicals warrant a rational use of these drugs, preferably by tailoring them to the individual patient. The objective was to…
Abstract Number: 1833 • 2012 ACR/ARHP Annual Meeting
Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate
Frank Zhang¹, Robert Hiscock² and Jeffrey R. Curtis³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²Analysis Group, Inc., Montreal, QC, Canada, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Several treatment options are available for psoriatic arthritis (PsA) patients (pts). The healthcare cost associated with the management of PsA pts varies depending on…
Abstract Number: 1834 • 2012 ACR/ARHP Annual Meeting
Utilization and Expected Cost of Rheumatoid Arthritis Patients Treated with Golimumab: A Specialty Pharmacy Perspective
Lorie Ellis¹, Susan Bolge², Heidi Hanna³, Christina White³ and Patricia Rice⁴, ¹Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Diplomat Specialty Pharmacy, Flint, MI, ⁴Statistics, CliniRx Research, Naperville, IL
Background/Purpose: Golimumab is a 50 mg, once-monthly, patient-administered anti-tumor necrosis factor alpha (anti-TNF) therapy indicated for moderate to severe rheumatoid arthritis (RA), active psoriatic arthritis,…
Abstract Number: 1835 • 2012 ACR/ARHP Annual Meeting
Prescription of Biologics in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) in 4 Norwegian Regions 2002-2011: A Study of Prescription Rates and Baseline Disease Activity
Elisabeth Lie¹, Karen M. Fagerli², Knut Mikkelsen³, Åse S. Lexberg⁴, Erik Rødevand⁵, Till Uhlig¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, Oslo, Norway, ³Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁵Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway
Background/Purpose: Biologics have constituted a major advance in the treatment of RA, PsA and AS. In Norway access to these therapies has been good since…
Abstract Number: 1836 • 2012 ACR/ARHP Annual Meeting
Early Versus Delayed Initiation of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Sharon Van Doornum¹, Lynden Roberts², Mark D. Reed³ and Danny Liew⁴, ¹Department of Medicine (RMH/WH), The University of Melbourne, Melbourne, Australia, ²School of Medicine, James Cook University, Townsville, Australia, ³Rheumatology, Sir Charles Gairdiner Hospital, Nedlands, Australia, ⁴Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia
Background/Purpose: Studies from a number of countries suggest that the time between symptom onset and initiation of DMARD therapy in RA patients is still longer…
Abstract Number: 1837 • 2012 ACR/ARHP Annual Meeting
Which Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis Patients Initiate Anti-TNFá Therapy?
Alain Saraux¹, Jacques Benichou², Chantal Deslandre³, Loic Guillevin⁴, Latifa Idbrik⁵, Jean Sibilia⁶, Marc Soudan⁵, Daniel Wendling⁷ and Francis Guillemin⁸, ¹Rheumatology, CHU de la Cavale Blanche and Université Bretagne occidentale, Brest Cedex, France, ²INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, EA4438 Laboratoire Physiopathologie des Arthrites, Rouen, France, ³Rheumatology, Cochin Hospital, Paris, France, ⁴Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ⁵Ecole de Sante Publique, Faculte de Medecin/BP 184, Vandoeuvre-les-Nancy, France, ⁶Université de Strasbourg, EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, ⁷Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ⁸Hopitaux de Brabois, Nancy, France
Background/Purpose: Comprehensive guidelines for anti-TNFα were proposed in 2005 by the French Society for Rheumatology (SFR) in France; they did not include any economic considerations…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].